Toronto, Ontario – (Newsfile Corp. – February 23, 2021) – Aion Therapeutic Inc. (CSE: AION) (“”Aion Therapeutic“or the”Business“) today announced the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The center will initially specialize in the use of psilocybin for the treatment of substance abuse (tobacco, alcohol and other drug abuse), depression and anxiety associated with life-threatening illnesses. In addition, the Center will study the efficacy of psilocybin as a new treatment for opioid dependence, Alzheimer’s disease, post-traumatic stress disorder (PTSD) and anorexia nervosa.
The US Food and Drug Administration (FDA) recently designated psilocybin treatment as a “breakthrough therapy” for the treatment of MDD. “MDD is a major public health problem affecting more than 300 million individuals worldwide. Depression is the leading cause of disability, and the relative risk of death from all causes for those with depression is 1.7 times greater than the risk to the general public.” In the United States, about 10% of the adult population has been diagnosed with MDD in the past 12 months, and the annual financial burden for MDD is estimated at $ 210 billion. “ “In the 36 largest countries in the world, in the absence of scaled-up treatment, it is estimated that more than 12 billion days of lost productivity (equivalent to more than 50 million years of work) can be attributed to depression and anxiety disorders each year, at an estimated cost of 925 “Given that the same distribution of costs across lower-income and higher-income countries holds for all other countries (representing 20% of the world’s population), the global cost per year is $ 1.15 trillion.”
The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, MD, MPH, DM, ICAP Dr. De La Haye is an Assistant Dean of the Faculty of Medical Sciences, University of the West Indies (UWI), Mona, Jamaica and a General Consultant and Addiction Psychiatrist at the University Hospital of the Caribbean (UHWI). He completed his doctorate (Cum Laude) at the University of Pecs in Hungary, his doctorate in psychiatry at UWI, his master’s degree in public health (Cum Laude) and a Fulbright Fellowship in substance abuse at Johns Hopkins University (JHU). He is an internationally certified addict addict and a global master trainer for substance abuse therapists.
Dr. De La Haye is a former Chief Medical Officer at the Ministry of Health and Welfare in Jamaica, a member of the Jamaica Medical Council, a member of the International Society for Substance Use Professionals (ISSUP), former president of the Jamaica Medical Association Former president of the Jamaica Psychiatric Association, former president for the Jamaica Fulbright Alumni Association, former chairman of the Bellevue Hospital Board of Management and former vice chairman of the National Council on Drug Abuse in Jamaica.
Dr. De La Haye set up the Medical Cannabis Unit of the Ministry of Health and Welfare (MOHW) in July 2017 and oversaw the registration of over 80 medical cannabis products in Jamaica. He is also a former captain of the Jamaica Defense Force.
Dr. De La Haye said: “We all need accessible and effective products for the treatment of patients with mental illness. Psychedelic psychiatry has the potential to change the lives of millions of patients, reduce their disabilities and improve their quality of life.” Dr. De La Haye continued, “As the Johns Hopkins Alumnus, it is our intention to follow the best treatment protocols such as those established at the Johns Hopkins Center for Psychedelic and Consciousness Research.”
Aion International Center for Psychedelic Psychiatry, in addition to treating patients, looks forward to collaborating with UWI and other tertiary institutions in Jamaica in the research and development of advanced, effective and safe products for the treatment of patients with mental illness. We also realize the importance of regulating the psychedelic industry and look forward to working closely with MOHW in Jamaica as they move towards setting up this very important regulatory body.
Dr Stephen Barnhill, President of Aion Therapeutic, said: “We are very pleased to be able to open the first International Center for Psychedelic Psychiatry in Jamaica. The center is unique in our ability to treat patients with both psilocybin and medical cannabis combination therapy. Produced for present at Aion Therapeutic in partnership with our licensed medical cannabis partner Apollon Therapeutics Jamaica, Ltd. We establish treatment protocols and dosing schedules for international expansion and export as and where the legal use of these products continues to expand globally. “Dr. Barnhill continued:” We are honored over having Dr. Winston De La Haye, with his significant expertise in addiction medicine as the medical director of the treatment facility. “
Mr Graham Simmonds, Vice President and CEO of Aion Therapeutic, said: “This is a very exciting time for the company as we now begin to treat patients and further develop our science and research with another excellent physician added to our team.” He added: “Our team, led by Dr. Barnhill, has worked tirelessly for the past six months to develop our research, develop our formulations, patent these formulations and develop an operational plan for the treatment of patients with additional medical conditions including cancer, inflammatory conditions. We will have updates with further information on our strategy to expand our treatment markets and manage our soon to be released intellectual property portfolio. I commend them for this important milestone and we look forward to seeing further progress from this world-class team we now have in place. “
Aion’s International Center for Psychedelic Psychiatry will soon open to see both Jamaican and international patients. In addition, we are planning a big opening party for a very near future. The grand opening date will be based on the lifting of the COVID-19 restrictions.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly Osoyoos Cannabis Inc.) has a joint venture agreement with a private, vertically integrated licensed producer under Cannabis Act (Canada) to provide services for the extraction of contract customs duties to third party companies. In addition, the company recently acquired 1196691 BC Ltd. d / b / a “PCAI Pharma” (www.pcai.ca) and its wholly owned subsidiary AI Pharmaceuticals Jamaica Limited, a private company incorporated and operating under Jamaican law. AI Pharma’s activities include research and development, treatment, data mining and state-of-the-art technology for artificial intelligence (machine learning), focusing on the development of combinatorial drugs, nutraceuticals and cosmeceuticals using cannabis compounds (cannabinoids), psychedelic mushrooms (psilocybin), mushrooms (edible fungi), natural psychedelic formulations (Ayahuasca) and other medicinal plants in a legal environment for this type of discovery. In addition, the company creates a strong international portfolio of intellectual property rights related to their discoveries.
For further information, please contact:
Aion Therapeutic Inc.
Vice Vice President & CEO
DISCLAIMER & READER ADVICE
Some statements in this press release constitute forward-looking information. These statements refer to future events or future results. The use of any of the words “could”, “think”, “expect”, “believe”, “will”, “get”, “projected”, “appreciated” and similar expressions and statements concerning issues that are not historical facts are intended to identify forward-looking information and are based on the company’s current beliefs or assumptions about the outcome and timing of such future events. Actual future results may differ significantly. In particular, this edition contains forward-looking information concerning the company’s operations. Different assumptions or factors are usually used to draw conclusions or make predictions or forecasts in forward-looking information. These assumptions and factors are based on information currently available to the parties. The essential factors and assumptions include regulatory approval and other third parties; licensing and other risks. The forward-looking information in this release is made from that date and the parties are not obligated to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Due to the risks, uncertainties and assumptions involved, investors should not rely too much on forward-looking information. The above statements expressly qualify all forward-looking information contained herein.
Journal of Clinical Psychiatry. 2015; 76 (2): 155-162
 Lancet Psychiatry 3: 415-24
Visit the source version of this press release https://www.newsfilecorp.com/release/75204
More Tags We LoveAuto insurance ca Banks near me to open account Uber food delivery job Medical assistant classes atlanta Buy stocks online app Online master degree in psychology Executive education academy charter school Student loan for college subsidized Screen repair tape Attorney general usa